These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7484303)

  • 1. [Cannabis and alcohol use as prognosis factors in the short-term progress of schizophrenia].
    Martínez Arévalo MJ; Varo Prieto JR; Aguinaga Aguinaga M; Calcedo Ordóñez A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1995; 23(4):189-92. PubMed ID: 7484303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug use and dependence in schizophrenia].
    Arias Horcajadas F; Padín Calo JJ; Fernández González MA
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(6):379-89. PubMed ID: 9477606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prospective study of favorable factors in follow-up of drug addicted patients--apropos of 257 patients of the Cassini Center in Paris].
    Goeb JL; Coste J; Bigot T; Ferrand I
    Encephale; 2000; 26(6):11-20. PubMed ID: 11217533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].
    Liraud F; Verdoux H
    Encephale; 2002; 28(2):160-8. PubMed ID: 11972143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.
    Suzuki K; Awata S; Takano T; Ebina Y; Iwasaki H; Matsuoka H
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):481-9. PubMed ID: 16048455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Schizophrenia and cannabis consumption: epidemiology and clinical symptoms].
    Jockers-Scherübl MC
    Prax Kinderpsychol Kinderpsychiatr; 2006; 55(7):533-43. PubMed ID: 17058779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study.
    Harrow M; Jobe TH
    J Nerv Ment Dis; 2007 May; 195(5):406-14. PubMed ID: 17502806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substance abuse and the onset of schizophrenia.
    Hambrecht M; Häfner H
    Biol Psychiatry; 1996 Dec; 40(11):1155-63. PubMed ID: 8931919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is cannabis a vulnerability factor in schizophrenic disorders].
    Laqueille X
    Arch Pediatr; 2009 Sep; 16(9):1302-5. PubMed ID: 19640690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse.
    Jockers-Scherübl MC; Rentzsch J; Danker-Hopfe H; Radzei N; Schürer F; Bahri S; Hellweg R
    Neurosci Lett; 2006 Jun; 400(3):262-6. PubMed ID: 16540246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A typology of cannabis-related problems among individuals with repeated illegal drug use in the first three decades of life: Evidence for heterogeneity and different treatment needs.
    Wittchen HU; Behrendt S; Höfler M; Perkonigg A; Rehm J; Lieb R; Beesdo K
    Drug Alcohol Depend; 2009 Jun; 102(1-3):151-7. PubMed ID: 19362792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective relations between melancholia and substance use disorders.
    Leventhal AM; Lewinsohn PM; Pettit JW
    Am J Drug Alcohol Abuse; 2008; 34(3):259-67. PubMed ID: 18428068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial.
    Potvin S; Stip E; Lipp O; Elie R; Mancini-Marië A; Demers MF; Roy MA; Bouchard RH; Gendron A
    Curr Med Res Opin; 2006 Jul; 22(7):1277-85. PubMed ID: 16834826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relevance of drug use in clinical manifestations of schizophrenia].
    Arias Horcajadas F; Sánchez Romero S; Padín Calo JJ
    Actas Esp Psiquiatr; 2002; 30(2):65-73. PubMed ID: 12028938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study of substance dependence comorbidity in bipolar, schizophrenic and schizoaffective disorders].
    Verdoux H; Mury M; Besançon G; Bourgeois M
    Encephale; 1996; 22(2):95-101. PubMed ID: 8706627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Untreated PTSD in schizophrenia - unrecognized risk factor for recovery and course of illness?].
    Vauth R; Nyberg E
    Fortschr Neurol Psychiatr; 2007 Aug; 75(8):463-72. PubMed ID: 17380464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term stability of alcohol and other substance dependence diagnoses and habitual smoking: an evaluation after 5 years.
    Culverhouse R; Bucholz KK; Crowe RR; Hesselbrock V; Nurnberger JI; Porjesz B; Schuckit MA; Reich T; Bierut LJ
    Arch Gen Psychiatry; 2005 Jul; 62(7):753-60. PubMed ID: 15997016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Do alcohol or drug abuse induce schizophrenia?].
    Hambrecht M; Häfner H
    Nervenarzt; 1996 Jan; 67(1):36-45. PubMed ID: 8676987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychiatric morbidity in the first-degree relatives of schizophrenic patients.
    Varma SL; Sharma I
    Br J Psychiatry; 1993 May; 162():672-8. PubMed ID: 8149120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County.
    Allebeck P; Adamsson C; Engström A; Rydberg U
    Acta Psychiatr Scand; 1993 Jul; 88(1):21-4. PubMed ID: 8372691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.